Precipio, Inc. (PRPO)

Precipio, Inc.'s stock has significantly appreciated, with its share price increasing by 427.20% from May 6, 2025, to May 5, 2026. The company's COO made an open-market purchase of common stock in April 2026. Precipio announced Q1 and Q4 2025 shareholder update calls in May and March 2026, respectively. A joint study with Memorial Sloan-Kettering Cancer Center was published in March 2026, highlighting Precipio's Bloodhound BCR::ABL1 Assay. The company reported that its unaudited revenues for 2025 grew to $24.0 million, a 30% increase year-over-year, and took major steps toward a clean balance sheet by reaching positive cash flow and repaying the Change Healthcare loan in 2025.

Precipio, Inc. experiences demand seasonality for its products and services. The company's Q1 2025 earnings call indicated that the sequential quarter-over-quarter decline in revenue from Q4 2024 to Q1 2025 is a typical seasonal pattern. Management expects revenue growth to resume in Q2 and accelerate in the second half of 2025, driven by new customer acquisition and increased purchases of new panels by existing customers.

Precipio, Inc. is a healthcare biotechnology company specializing in cancer diagnostics, focusing on improving diagnostic accuracy and efficiency to reduce misdiagnoses. Its major products and services include diagnostic blood cancer testing services, the HemeScreen suite of genetic diagnostic panels, IV-Cell, and biomarker testing and clinical project services.

Precipio, Inc.'s laboratory and R&D facilities are located in New Haven, Connecticut, and Omaha, Nebraska. The company provides blood cancer diagnostics across many states in the United States and launched a global expansion strategy in 2019, targeting countries such as India, China, Malaysia, the Gulf countries in the Middle East, and various European countries.

Precipio's brand reputation has been positively impacted by the publication of a joint study with Memorial Sloan-Kettering Cancer Center, highlighting the effectiveness of its Bloodhound BCR::ABL1 Assay. However, the company's 2025 annual report included a "going concern" warning due to recurring operating losses, which could pose a risk to its reputation and investor confidence. Management anticipates that the removal of this "going concern" language, likely in early 2026, could allow certain institutional investors to invest in the company.

Precipio, Inc.'s ownership structure includes a mix of institutional, retail, and individual investors. Major institutional owners include Topline Capital Management, LLC, BlackRock, Inc., Vanguard Group Inc, Geode Capital Management, Llc, Renaissance Technologies Llc, Evernest Financial Advisors, LLC, Tower Research Capital LLC (TRC), UBS Group AG, Jones Financial Companies Lllp, Wells Fargo & Company/mn, AMH Equity, Ltd., Dimensional ETF Trust, and DFA Investment Dimensions Group Inc. Significant individual and insider owners of Precipio, Inc. include Randal J. Kirk, Steven R. Becker, Collin J. Dsilva, Leroy C. Kopp, Mark Rimer, Kevin Douglas, Ilan Danieli, Richard A. Sandberg, Chad M. Richards, and David Seth Cohen. Ilan Danieli, the CEO, also holds a notable number of shares.